Abstract: There is provided a device for measuring an amount of snowfall in consideration of a weight of the snowfall, comprising: a housing; a snow depth measuring unit configured to measure a depth of the snowfall outside the housing; a snow holding container configured to hold the snowfall whose depth has been measured by the snow depth measuring unit, wherein at least part of the snow holding container is positioned inside the housing; a heating unit configured to melt the snowfall held in the snow holding container, wherein the heating unit is formed in or on at least part of the snow holding container; and a snow weight measuring unit configured to hold meltwater and to measure a weight thereof, wherein the meltwater has been acquired by melting the snowfall with the heating unit.

Abstract: A vehicle body structure for safely protecting a high-voltage, the vehicle body structure including: a battery mounted on bottom portions of a center floor and a rear floor; and a protective structure having a bottom portion on which a peripheral portion of the battery is mounted and including panels fitted to each other into a shape covering a peripheral portion of the center floor.

Abstract: Aspects of the present disclosure relate to methods and compositions related to the preparation of immune cells, including engineered immune cells. Certain embodiments of the disclosure include compositions, cells, and methods related to engineered invariant natural killer T (iNKT) cells for off-the-shelf use for clinical therapy. The iNKT cells may be produced from hematopoietic stem progenitor cells and may be suitable for allogeneic cellular therapy because they are HLA negative. In some aspects, the cells have imaging and suicide targeting capabilities.

Abstract: A vehicle body structure for safely protecting a high-voltage, the vehicle body structure including: a battery mounted on bottom portions of a center floor and a rear floor; and a protective structure having a bottom portion on which a peripheral portion of the battery is mounted and including panels fitted to each other into a shape covering a peripheral portion of the center floor.

Abstract: The present invention relates to a combination formulation containing metformin for treating non-insulin-dependent diabetes and an HMG-CoA reductase inhibitor for treating dyslipidemia. The present invention provides a combination formulation and a method for preparing the combination formulation, wherein the combination formulation contains metformin and an HMG-CoA reductase inhibitor.

Abstract: Compositions are provided including NK cells that express chimeric antigen receptors (CARs) specific to CD19 and Her2 and a plurality of cell surface-bound multilamellar liposomal vesicles loaded with one or more anti-cancer therapeutics at an effective amount for inhibiting or killing tumor cells without causing toxicity to the NK cells. Methods of using these compositions to treat a subject with tumor are also provided, including administering an effective amount of the CAR-engineered NK cells, where an effective amount of anti-tumor therapeutics are delivered in particles (e.g., crosslinked multilamellar liposomal vesicles) that are bound to the surface of these CAR-engineered NK cells, without causing toxicity to the carrier NK cells.

Abstract: Described herein are compositions including an immune effector cells that are chemically modified at the surface with one or more active agent-loaded nano- or micro-particles for controlled release of the active agent. Exemplary drug-loaded nanoparticles include crosslinked multilayer liposome (CMLV) encapsulating an A2a receptor inhibitor. The modified immune effector cells may also present one or more chimeric antigen receptors (CARs) on the surface. Also provided are methods of using the same to treat cancer.

Abstract: The present invention relates to a gastric-retention type sustained-release formulation of metformin as an insulin-independent diabetic agent, and a preparation method thereof. More specifically, the present invention relates to a gastric-retention type sustained-release formulation, which can effectively control drug release even with a small amount of a polymer by forming a sustained-release granulated material, which comprises granules containing metformin or a pharmaceutically acceptable salt thereof and a swellable polymer, and a water-insoluble coated on the surface of the granules; and also can allow a tablet containing the drug to swell rapidly at an early stage by formulating via mixing of a superdisintegrant, which is capable of controlling the speed of gelation forming hydrogels, with the granulated material; and a preparation method thereof.

Abstract: The present invention relates to a combination formulation containing metformin for treating non-insulin-dependent diabetes and an HMG-CoA reductase inhibitor for treating dyslipidemia. The present invention provides a combination formulation and a method for preparing the combination formulation, wherein the combination formulation contains metformin and an HMG-CoA reductase inhibitor, and has effectively improved stability by blocking physical and chemical reactions between the active ingredients while securing the stable release of respective active ingredients.

Abstract: Provided are an apparatus for integrated real-time nucleic acid analysis and a method for detecting target a nucleic acid using the same, and more particularly an integrated real-time nucleic acid analysis for simultaneously performing qualitative analysis or quantitative analysis on genes from various kinds of plural biological samples and a method for detecting target a nucleic acid using the same. The apparatus for integrated real-time nucleic acid analysis and the method for detecting target a nucleic acid using the same according to the present invention, perform tests of various targets required from various samples through a single step promptly and accurately, and thus, can be efficiently used by hospitals or the like needing to rapidly diagnose diseases.